GordonMD Global Investments LP
Long book
$143.6M
Q1 2026
Positions
16
Top-10 weight
82%
concentration
Last quarter
+17.7%
SPY +14.8%
Turnover
19%
of book per quarter
Strategy in plain words
auto-generated from filingsGordonMD Global Investments LP is a concentrated fundamental stock-picker, specialised in healthcare (96% of the long book), running a $143.6M US long book across 16 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: KYVERNA THERAPEUTICS INC, TAYSHA GENE THERAPIES INC, VIR BIOTECHNOLOGY INC, BAUSCH + LOMB CORP, AMGEN INC.
We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2025
-3.7%
Q1 2026
+17.7%
Sector allocation
Healthcare 96%
Materials 4%
Long book by quarter
What does GordonMD Global own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| KYTX KYVERNA THERAPEUTICS INC | Healthcare | 4.2M | $36.6M | 25.5% | -3.3% |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 737.5K | $22.2M | 15.5% | -44.6% |
| VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.5M | $13.6M | 9.5% | +63.2% |
| BLCO BAUSCH + LOMB CORP | Healthcare | 573.5K | $9.1M | 6.4% | -6.5% |
| AMGN AMGEN INC | Healthcare | 20.2K | $7.1M | 5.0% | -12.9% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 132.5K | $6.5M | 4.5% | New |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 289.1K | $6.1M | 4.2% | -12.2% |
| PYXS PYXIS ONCOLOGY INC | Healthcare | 4.1M | $6.0M | 4.2% | Held |
| SION SIONNA THERAPEUTICS INC | Healthcare | 136.0K | $5.5M | 3.8% | New |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 170.3K | $5.4M | 3.8% | Held |
| INSM INSMED INC | Healthcare | 28.6K | $4.7M | 3.3% | Held |
| CRNX CRINETICS PHARMACEUTICALS IN | Healthcare | 127.0K | $4.6M | 3.2% | -43.3% |
| INCY INCYTE CORP | Healthcare | 43.3K | $4.1M | 2.8% | -20.6% |
| ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 1.4M | $3.5M | 2.4% | New |
| TARS TARSUS PHARMACEUTICALS INC | Healthcare | 42.7K | $3.0M | 2.1% | -36.0% |